Dexamethasone — Drug Intelligence | 198 EU Trials

Filter these 198 trials by condition, phase, country and more.

Open in Search →

198 Registered trials

72 Recruiting

106 Completed trials

90 Sponsors

27 Countries

Phase III

Phase II

Phase I/II

Phase III: 89 Phase II/III: 8 Phase II: 64 Phase I/II: 19 Phase III/IV: 4 Phase IV: 8 Phase I: 2 Phase I (FiH): 4

Oversight events:

6 serious breaches 95 temporary halts 12 urgent safety measures 7 unexpected events 11 corrective measures across 31 trials

View oversight register →

Indications tested

Plasma cell myeloma 6 Plasma cell myeloma refractory 4 Non-small cell lung cancer 3 Diffuse large B-cell lymphoma 3 Prostate cancer metastatic 3 Dermatomyositis 2 Polymyositis 2 Relapsing multiple sclerosis 2 Diffuse large B-cell lymphoma stage II 1 Endolymphatic hydrops 1 Hormone receptor positive breast cancer 1 Injection site pain 1

Sponsors using this IMP

Janssen - Cilag International 13 Celgene Corp. 12 Pfizer Inc. 10 Sanofi-Aventis Recherche & Developpement 9 Regeneron Pharmaceuticals Inc. 8 European Myeloma Network B.V. 7 Fundacion PETHEMA 7 AbbVie Deutschland GmbH & Co. KG 6 Amgen Inc. 6 Centre Hospitalier Universitaire De Nantes 6 Emn Trial Office S.r.l. Impresa Sociale 6 Glaxosmithkline Research & Development Limited 6

All trials

198 total

Phase 1b/2a Study to Evaluate Alnuctamab in Combination with Mezigdomide in Relapsed and/or Refractory Multiple Myeloma. Not authorised

2023-504367-16-00 Phase II 1 country Celgene International II S.a.r.l.
Searching for the right dose of perineural dexmedetomidine for a interscalene plexus block. Not authorised

2023-506062-31-00 Phase III/IV 1 country Algemeen ziekenhuis Rivierenland
APICALE - Cervical facet injection of corticosteroids for the management of cervicobrachialgia : protocol for a randomized pilot study Pending

2024-511790-30-00 Phase III 1 country Assistance Publique Hopitaux De Paris
MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending

2024-513889-19-00 Phase III 2 countries Intergroupe Francophone Du Myelome
Daratumumab in Combination with Carfilzomib, Pomalidomide and Dexamethasone in patients with myeloma induced acute renal failure Pending

2024-514702-31-00 Phase II 1 country Medizinische Universitaet Innsbruck
A multi-center open-label phase 2 study of Ixazomib, Iberdomide and dexamethasone in elderly patients with multiple myeloma at first relapse Pending

2024-516257-44-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
ASSESSMENT OF THE EFFECT OF DEXAMETHASONE INTRAORAL AND EXTRAORAL IN THE SURGERY OF RETAINED LOWER THIRD MOLARS. Pending

2024-517000-11-00 Phase IV 1 country Complutense University Of Madrid
A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/… Pending

2024-518275-64-00 Phase II 1 country Instytut Hematologii I Transfuzjologii
Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple my… Pending

2024-519353-11-00 Phase II 1 country Landspitali
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending

2024-519504-27-00 Phase III 10 countries Regeneron Pharmaceuticals Inc.
Dexamethasone for the treatment of traumatic brain injured patients with brain contusions and pericontusional edema: Study protocol for a pr… Pending

2025-520887-17-00 Phase IV 1 country University Hospital Son Espases
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refrac… Pending

2025-521090-14-00 Phase II 1 country Assistance Publique Hopitaux De Paris
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL Pending

2025-522019-40-00 Phase I/II 7 countries Novartis Pharma AG
A Trial to Study if REGN17372 in Combination with Linvoseltamab is Tolerable for Adult Participants with Relapsed/Refractory Multiple Myelom… Pending

2025-522776-93-00 Phase I 1 country Regeneron Pharmaceuticals Inc.
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending

2025-523285-25-00 Phase III 6 countries AstraZeneca AB
A study investigating the safety and efficacy of academically-produced CAR T cells compared with standard treatment for patients with multip… Pending

2025-524876-43-00 Phase III 1 country Universitair Medisch Centrum Groningen
Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE) Pending

2026-525263-41-00 Phase III 1 country Polska Grupa Badawcza Chloniakow
A study to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care in participants aged 18 years and o… Recruiting

2025-523117-28-00 Phase II 5 countries Glaxosmithkline Research & Development Limited
A Global Study Testing the New Drug Olverembatinib combined with chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Pos… Recruiting

2024-511496-14-00 Phase III 8 countries Ascentage Pharma Group Inc.
A study to compare Efficacy, Safety and How the Body Absorbs, Distributes, and Eliminates of Subcutaneous CT-P44 and Darzalex Faspro in Comb… Recruiting

2024-518588-36-00 Phase III 2 countries Celltrion Inc.
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting

2023-508015-23-00 Phase III 14 countries Merck Sharp & Dohme LLC
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting

2023-506235-15-00 Phase III 12 countries Amgen Inc.
Cataract surgery and Inflammation – the role for preoperative NSAIDs (pre-CIN) Recruiting

2024-512268-77-00 Phase IV 1 country Oslo University Hospital HF
A Phase 3 Study With Randomized Withdrawal/Dose Up Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants With… Recruiting

2023-505804-42-00 Phase III 5 countries Pfizer Inc.

Showing 1–24 of 198 trials

← All drugs A–Z